FABP4 and diabetes mellitus: Consistently, fasting insulin level in BMS309403-treated mice was also higher compared with that in vehicle-treated mice (Figure 3F), suggesting that pharmacological inhibition of FABP4 from an early age is sufficient to ameliorate β cell destruction and diabetes in NOD mice.